Eli Lilly and Co
Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
During the October Monthly Meeting , we took questions directly from Investing Club members. Here are Jim Cramer’s and portfolio director Jeff Marks’ responses. Their answers have been edited for clarity. 1. Why do rising interest rates have such a negative effect on technology stocks? (Rod) Jim Cramer: When the Federal Reserve started raising rates, […]
Read More
Here’s a rapid-fire update on all 36 stocks in our portfolio, including our latest addition
Jim Cramer ran through the names during the Club’s October Monthly Meeting on Wednesday. Source
Read More
15 stocks with a history of dividend growth are expected to deliver once again this year
Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley strategists […]
Read More
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. The drugs are once-weekly injectables of a medication called semaglutide, prescribed for Type 2 diabetes and weight loss. Their skyrocketing popularity has boosted Novo Nordisk to new heights. Novo Nordisk’s […]
Read More
Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world’
CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest pharmacy issue [is] how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex,” Cramer said […]
Read More
Stocks generating the most significant moves midday: Meta, Warby Parker, McCormick and additional
McCormick spices are exhibited on a shelf at a grocery store in San Anselmo, California, on March 28, 2023. Justin Sullivan | Getty Photos News | Getty Pictures Verify out the providers making headlines in midday investing. Warby Parker — The eyewear maker popped 3.4% just after Evercore ISI upgraded shares to outperform from in […]
Read More
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
Aykut Karahan | Istock | Getty Images Shares of Structure Therapeutics rose more than 30% on Friday after the biotech startup’s experimental obesity pill succeeded in a small early-stage trial. The once-daily drug helped overweight or obese participants reduce up to 10 pounds of weight on average after four weeks of treatment, according to a […]
Read More
Will weight loss drugs lead to less food consumption? Here’s what Walmart is saying
More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and Ozempic […]
Read More
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during […]
Read More
Health care has had a tough year. Where we stand on our 5 stocks in the sector
There’s Eli Lilly (LLY), and then there’s everybody else. That’s a simple way to describe the performance of the Club’s health-care holdings so far this year, in what’s been a challenging period for the industry overall. Of the 11 market sectors year to date, health care is the fourth worth-worst performer, falling 4%, followed by […]
Read More